Can your platform handle solid tumor targets with low antigen density?

Yes. We utilize high-sensitivity signaling domains like DAP12 and optimized hinge regions to trigger a potent lytic response even at lower thresholds, ensuring efficacy against heterogeneous cancer stem cell populations.

Is the iPSC-derived CAR-NK product truly 'off-the-shelf'?

Absolutely. Our engineered master cell banks are designed for massive expansion into billions of homogenous doses, providing a scalable and ready-to-use therapeutic solution that eliminates the complexities of patient-specific manufacturing.

Cancer Stem Cell targeted CAR-NK Design & Validation Service

Q: How do you prevent 'on-target, off-tumor' toxicity against healthy stem cells?

We implement sophisticated logic-gated circuits to ensure activation occurs only within the specific antigenic signature of the tumor, effectively shielding healthy progenitor cells from unwanted off-target immune attacks.

Creative Biolabs provides a sophisticated pipeline to eradicate the cancer stem cell (CSC) niche. We engineer CAR-NK candidates with high-affinity binding and metabolic resilience to neutralize quiescent drivers of malignancy. By integrating the innate "missing-self" recognition of natural killer cells with chimeric precision against markers like CD133, CD44v6, and EpCAM, our platform overcomes the heterogeneity and immune-evasive tactics of solid tumors. Our end-to-end service ensures robust validation of candidates designed to prevent relapse.

The CAR-NK Advantage in CSC Eradication

Creative Biolabs leverages CAR-NK cells as a superior chassis for CSC eradication. These cells utilize a multi-faceted killing strategy: direct CAR-targeted specificity, granule exocytosis, and death receptor signaling to eliminate even antigen-low subpopulations. NK platforms offer a superior safety profile with minimal CRS/ICANS risk, enabling "off-the-shelf" allogeneic applications. Furthermore, we engineer NK cells with matrix metalloproteinases (MMPs) and CXCR1/CXCR2 to penetrate the dense extracellular matrix of the CSC niche, overcoming physical barriers that hinder traditional cell therapies.

Comprehensive Service Portfolio

Creative Biolabs delivers a modular and highly customizable service suite designed to address every technical hurdle in the development of CSC-targeted therapies. Our offerings are anchored in the latest breakthroughs in synthetic biology and pluripotent stem cell technology.

Custom CSC-Targeted CAR Engineering

We design and construct chimeric receptors optimized for the NK cell signaling environment. This includes the selection of high-affinity scFvs antibodies against CSC markers and the integration of specialized costimulatory domains (e.g., 2B4, DAP12) that drive superior NK cell activation and cytokine production.

"Off-the-Shelf" iPSC-NK Platform

To resolve the issues of donor variability and manufacturing scalability, we offer a master cell bank approach using engineered iPSCs. This provides a homogenous, high-purity effector cell population that can be expanded into billions of doses, ready for immediate therapeutic application.

Logic-Gated Circuit Development

To minimize "on-target, off-tumor" effects on healthy stem cell populations, we offer the design of sophisticated "AND," "OR," and "NOT" logic gates. These circuits ensure that CAR-NK activation occurs exclusively within the specific antigenic signature of the tumor niche.

Tumor Microenvironment (TME) Armoring

We provide genetic "armoring" services, including the co-expression of membrane-bound cytokines (IL-15/IL-21) and the knockout of inhibitory receptors (NKG2A/TIGIT/PD-1) to ensure your cells remain active and persistent in the immunosuppressive, hypoxic tumor core.

High-Fidelity Validation Assays

Our validation suite includes real-time 3D organoid lysis monitoring, limiting dilution assays (LDA), and secondary sphere formation tests. These assays provide definitive proof of the treatment's ability to deplete the tumor-initiating cell frequency.

Workflow

Creative Biolabs has established a streamlined workflow that prioritizes precision engineering and high-fidelity testing, ensuring that every milestone provides actionable insights for your development program.

Publication

CAR-NK cell therapy emerges as a promising alternative to CAR-T for solid tumors, offering key advantages such as "off-the-shelf" readiness, a lower risk of cytokine release syndrome and neurotoxicity, and the ability to kill cancer cells through both antigen-dependent and independent mechanisms. While challenges like limited persistence and tumor infiltration remain, ongoing engineering strategies aim to enhance CAR-NK efficacy and safety for broader clinical application.

Fig.1 Strategies to overcome current limitations of CAR-NK cell therapy in solid tumors. (OA Literature)

Fig.1 Current hurdles and strategic approaches to enhance CAR-NK cell therapy in solid tumors. ¹

Why Choose Us?

Creative Biolabs offers an unparalleled advantage by integrating deep expertise in natural killer cell biology with advanced synthetic biology frameworks. Our "multi-hit" cytotoxic strategy is uniquely suited for solid tumors; while the CAR provides precise targeting, our engineered NK cells simultaneously utilize innate natural cytotoxicity receptors (NCRs) to detect "missing-self" signals in HLA-downregulated CSCs. This dual activation minimizes the risk of antigen escape, a common cause of therapeutic failure in traditional CAR-T programs. Furthermore, our premium iPSC-derived platform ensures 100% clonal homogeneity and eliminates the logistical burdens of donor-derived products. By establishing stable master cell banks, we provide a truly scalable, high-purity, and cost-effective "off-the-shelf" solution that accelerates your pipeline toward successful submission and preclinical implementation.

Experience the Creative Biolabs advantage firsthand—Speak with our oncology team to optimize your next project.

FAQs

Customer Review

Related Services

Metastatic Tumor Microbiome Analysis Services

Creative Biolabs provides metastatic tumor microbiome analysis. We utilize multi-omics and bioinformatics to elucidate microbial composition changes and their pleiotropic effects on cancer metastasis.

Learn More →

Potassium Ion Channel Assay Service

Creative Biolabs provides fluorescence and electrophysiology assays using engineered cell lines. We deliver precise screening for potassium channel activators, inhibitors, and modulators to accelerate drug discovery.